Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Abstract Background Epidermal growth factor receptor (EGFR) mutations in non–small-cell lung cancer predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation types are associated with efficacy of EGFR TKIs. We investigated the clinical outcomes of afatinib, erlotinib, and gefitini...

Full description

Bibliographic Details
Main Authors: Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Epidermal growth factor receptor
Non-small cell lung cancer
Adenocarcinoma
Survival
Tyrosine kinase inhibitor
Online Access:https://doi.org/10.1186/s12885-020-07765-6

Internet

https://doi.org/10.1186/s12885-020-07765-6

Similar Items